Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aligos Therapeutics

< Previous 1 2 Next >
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present at Investor Conferences in October
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS HAE NVO PLRX
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Reverse Stock Split
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Strengthens Board with Two New Independent Directors
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.